Sysmex Europe
Menu

Sentimag® - Magtrace® in melanoma

Melanoma is a skin cancer that develops from the pigment-producing cells of the skin and can occur anywhere on the body. In many cases it develops in skin often exposed to sunlight, such as the face, neck, hands and arms.

Melanoma is the most serious type of skin cancers as it is more prone to form metastases. Therefore, identifying if the cancer has spread - using sentinel lymph node biopsy (SLNB) - is a vital part of the cancer staging process. SLNB is the most important prognostic factor and the most sensitive and specific diagnostic procedure to determine the nodal involvement [1-4].  

Contrary to standard sentinel node localisation using radioisotoes, the Magtrace® lymphatic tracer uses safe magnetic fields. This helps to eliminate concerns related to safety and flexibility for both the clinician and patient, as well as the workflow and availability associated with ionising radiation. The flexibility of Magtrace® is really a key benefit because it enables SLNB to be performed anywhere and in a wider injection window.

First, the tracer is injected via intradermal injection. The tracer will migrate to the sentinel nodes and due to its traceable signal, the nodes containing Magtrace® can be identified using the magnetic sensor in the Sentimag® probe before being removed.

Magtrace® – an accurate clinical solution

  • Regardless of the hospital setting or facilities, provide the best standard of cancer staging
  • Convenience is key for both clinician and patient – inject the tracer anywhere from 20 minutes prior to surgery or up to 30 days in advance
  • Radioactivity is eliminated – while still reaching equivalent clinical outcomes [4,5]
  • Certified for intra-dermal injection
  • Intuitive magnetic identification as well as visual confirmation
  • Sentimag® and Magtrace® are FDA-cleared and CE-marked

 

Selected sources:

[1] SEER Cancer Stat Facts: Melanoma of the Skin. seer.cancer.gov/statfacts/html/melan.html  (accessed Apr. 19, 2021).


[2] Karakousis et al. (2017): Ann Surg Oncol. 24:952–959.
[3] Swetter et al. (2019): J Am Acad Dermatol. 80:208–250.
[4] Piñero-Madrona et al. (2020): J Surg Oncol. 1-6.
[5] Anninga et al. (2016). (2016): Ann Surg Oncol. 23(6):2070-8.

Endomag®, Sentimag® and Magseed® are registered European Union trademarks of Endomagnetics Ltd www.endomag.com

Magtrace® is a registered trademark of Endomagnetics Ltd in the United Kingdom www.endomag.com

Contact

Sysmex Europe GmbH

Bornbarch 1

22848 Norderstedt

Germany

+49 (40) 527 26 0

+49 (40) 527 26 100

Documents

Product documents

Regulatory Documents

Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login:

Go to My Sysmex

Explore more

Copyright © Sysmex Europe GmbH. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.